DOI: 10.12890/2025_005625

Nivolumab-induced chylothorax in a patient with advanced gastric adenocarcinoma

Authors

  • Youssef Hayssam Sultan Resident of Internal Medicine, University of Balamand, Beirut, Lebanon 0000-0002-7588-3093
  • Radwan Zeidan Pulmonary and Critical Care Fellow, University of Balamand, Beirut, Lebanon
  • Mohammed Abdallah Pulmonary and critical care fellow, University of Balamand, Beirut, Lebanon
  • Staphanie Joseph Mitri Pulmonary and critical care medicine, Balamand University, Mount Lebanon University Medical Center, Beirut, Lebanon
  • Francois Georges Kamar Haematology and Oncology Division, Department of Medicine, University of Balamand, Beirut, Lebanon; Hematology Oncology Department, Mount Lebanon University Medical Centre. Hazmieh, Lebanon

stephanie.joseph.mitri@gmail.com

Keywords

Nivolumab, chylothorax, immune adverse event, advanced gastric adenocarcinoma, PD-1 inhibitor

Abstract

Chylothorax refers to the presence of chyle in the pleural space leading to respiratory compromise. Chylothorax secondary to gastric adenocarcinoma or immune checkpoint inhibitors, such as nivolumab, is exceedingly rare and has been documented only in isolated case reports. The exact mechanism by which nivolumab may induce chylothorax remains unclear, though immune-mediated increased lymphatic permeability induced by anti-PD-1 has been hypothesised. This report highlights a unique presentation of chylothorax in a patient with gastric adenocarcinoma undergoing nivolumab therapy.

View the entire article

Downloads

References

  1. Valentine VG, Raffin TA. The management of chylothorax. Chest 1992;102:586–591. doi: 10.1378/chest.102.2.586
  2. Wongrukmit S, Ngamphaiboon N, Kiranantawat K, Suwanthanma W, Plumworasawat S, Boonsakan P, et al. Unusual manifestation of gastric adenocarcinoma presenting with lymphedema, chylothorax, and chylous ascites. Clin J Gastroenterol 2023;16:822–828. doi: 10.1007/s12328-023-01851-5
  3. Soerjomataram I, Cabasag C, Bardot A, Fidler-Benaoudia MM, Miranda-Filho A, Ferlay J, et al. SURVCAN-3 collaborators. Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries. Lancet Oncol 2023;24:22–32. doi: 10.1016/S1470-2045(22)00704-5
  4. Riihimaki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. Metastatic spread in patients with gastric cancer. Oncotarget 2019;7:52307–52316. doi: 10.18632/oncotarget.10740
  5. Janjigian YY, Ajani, JA, Moehler M, Shen L, Garrido M, Gallardo C, et al. First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the Phase III CheckMate 649 Trial. J Clin Oncol 2024;42:2012–2020. doi: 10.1200/JCO.23.01601
  6. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. J Clin Oncol 2021;39:4073–4126. doi: 10.1200/JCO.21.01440
  7. Neuville C, Aubin F, Puzenat E, Popescu D, Crepin T, Nardin C. Nivolumab-induced capillary leak syndrome associated with chylothorax in a melanoma patient: a case report and review of the literature. Front Oncol 2022;12:1032844. doi: 10.3389/fonc.2022.1032844
  8. Roviello F, Rossi S, Marrelli D, Pedrazzani C, Corso G, Vindigni C, et al. Number of LN metastases and its prognostic significance in early gastric cancer: a multicenter Italian study. J Surg Oncol 2006;94:275–280. doi: 10.1002/jso.20566
  9. Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc 2008;83:235–250. doi: 10.4065/83.2.235. Erratum in: Mayo Clin Proc 2009;84:847.
  10. Neuville C, Aubin F, Puzenat E, Popescu D, Crepin T, Nardin C. Nivolumab-induced capillary leak syndrome associated with chylothorax in a melanoma patient: a case report and review of the literature. Front Oncol 2022;12:1032844. doi: 10.3389/fonc.2022.1032844
  11. Qin H, Vlaminck B, Owoyemi I, Herrmann SM, Leung N, Markovic SN. Successful treatment of pembrolizumab-induced severe capillary leak syndrome and lymphatic capillary dysfunction. Mayo Clin Proc Innov Qual Outcomes 2021;5:670-674. doi: 10.1016/j.mayocpiqo.2021.01.004
  12. Lescure C, Lescoat A, Salé A, Bazin Y, Duvergé L, Desrues B, et al. Systemic capillary leak syndrome (Clarkson’s disease) as a complication of anti-programmed death 1 immunotherapy. J Thorac Oncol 2019;14:e131–132. doi: 10.1016/j.jtho.2019.02.003
  13. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245. doi: 1038/clpt.1981.154

Published

2025-09-08

Issue

Vol. 12 No. 10 (2025)

Categories

How to Cite

1.
Sultan YH, Zeidan R, Abdallah M, Mitri SJ, Kamar FG. Nivolumab-induced chylothorax in a patient with advanced gastric adenocarcinoma. EJCRIM [Internet]. 2025 Sep. 8 [cited 2026 Nov. 3];12(10). Available from: https://ejcrim.com/index.php/ejcrim/article/view/5625

Most read articles by the same author(s)